RAM
BBIO icon

Riggs Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Riggs Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44
Closed -$1.9K – 206
2025
Q2 		$1.9K Buy
+44
New +$1.6K ﹤0.01% 658

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riggs Asset Management's BBIO Position: Q3 2025 in Review

Riggs Asset Management sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 44 shares — an estimated $1.9K sold.

Riggs Asset Management first reported a position in BBIO in Q2 2025 and held it in 1 quarter. The position peaked at $1.9K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Riggs Asset Management reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 44 BridgeBio Pharma shares in Q3 2025, an estimated $1.9K.
  • Riggs Asset Management first reported a position in BridgeBio Pharma in Q2 2025 and held it in 1 quarter.
  • Riggs Asset Management's BridgeBio Pharma position peaked at $1.9K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.